Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

[1]  A. Hauschild,et al.  COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma , 2014 .

[2]  G. Pupo,et al.  Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma , 2014, Molecular oncology.

[3]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[4]  A. King,et al.  Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions , 2013, PloS one.

[5]  K. Flaherty,et al.  BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). , 2013 .

[6]  R. Sullivan,et al.  Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. , 2013 .

[7]  K. Flaherty,et al.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[10]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[11]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[12]  T. Gilmer,et al.  Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.

[13]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[14]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[15]  P. Mischel,et al.  Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway , 2011, PloS one.

[16]  B. Sikic,et al.  Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors , 2011 .

[17]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[18]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[19]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[20]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[21]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[22]  A. Hauschild,et al.  mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study , 2014 .

[23]  J. Wisell,et al.  Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma , 2013 .

[24]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .